Quantcast

Posts related to ‘Biotech’

Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)

Posted: November 3, 2011 at 10:59 am

Medivation, Inc. (NASDAQ: MDVN) is today's darling in biotech and emerging pharmaceuticals.  It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate. Its shares ...
Read Full Story »

Human Genome Sciences Back to Drinking from the Capital Well (HGSI)

Posted: November 2, 2011 at 7:39 am

Human Genome Sciences Inc. (NASDAQ: HGSI) is raising capital.  The company announced the sale of $400 million in Convertible Senior Notes which will mature in 2018. These notes are convertible into ...
Read Full Story »

Measuring Pre-Earnings Upside in Biotechs (DNDN, HGSI, GILD, AMLN, ARIA, INCY, IBB, XBI, BBH)

Posted: October 19, 2011 at 11:34 am

We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there is about to be a rush of earnings reports from ...
Read Full Story »

Does VIVUS Need This Cash From The Stock Offering? (VVUS, OREX, ARNA)

Posted: August 24, 2011 at 8:27 am

VIVUS, Inc. (NASDAQ: VVUS) is in the news this morning after entering into an agreements with a select group of institutional investors to sell 6,889,098 shares of its common ...
Read Full Story »

Why “Sell the News” on Seattle Genetics (SGEN)

Posted: August 22, 2011 at 1:17 pm

There is an old rule of thumb from biotech investors and traders... SELL FDA APPROVALS.  This is very counter-intuitive on the surface but we wanted to explain in more detail ...
Read Full Story »

Picking Apart the Dendreon Implosion (DNDN)

Posted: August 4, 2011 at 7:59 am

Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for prostate cancer.  The limited life-extension versus a high cost for ...
Read Full Story »

The Day After the Implosion: How Long Can Nabi Survive? (NABI)

Posted: July 19, 2011 at 3:34 pm

Nabi Biopharmaceuticals (NASDAQ: NABI) actually finds itself in a strange situation after Monday's awful news that its NicVAX nicotine conjugate immunotherapeutic failed to meet its primary endpoint in the first ...
Read Full Story »

Rethinking Cell Therapeutics… As An Acquirer? (CTICD)

Posted: May 26, 2011 at 10:03 am

Cell Therapeutics, Inc. (NASDAQ: CTICD) has long been a controversial stock.  It has brought many rewards for investors and it has also brought much pain to investors.  We recently featured ...
Read Full Story »

BioWatch: Cell Therapeutics Versus FDA, Before ASCO (CTICD)

Posted: May 24, 2011 at 7:40 am

Cell Therapeutics, Inc. (NASDAQ: CTICD) has been very active since its recent 1-for-6 reverse stock split took place on May 16, 2011.  Its share volume has increased on all but ...
Read Full Story »

Neostem Raising Cash For It and Holders (NBS)

Posted: May 3, 2011 at 9:51 am

Neostem, Inc. (AMEX: NBS) is a bit soft this morning after making two separate share sale filings with the SEC.  The company has filed to sell shares for existing holders ...
Read Full Story »

M&A Watch: Biotech Deals Keep Rolling, Who Is The Next Buyout Target? (TEVA, VRX, CEPH, CRA, ALXN, DNDN, CBST, HGSI, UTHR, CADX, AMAG, SGMO)

Posted: May 2, 2011 at 7:46 pm

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has trumped Valeant Pharmaceuticals International, Inc. (NYSE: VRX) after it agreed to acquire Cephalon Inc. (NASDAQ: CEPH) in a $6.8 billion deal.  The merger will give ...
Read Full Story »

Key Stocks To Watch For the Week Ahead, The Unusual Suspects (AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW)

Posted: May 1, 2011 at 1:33 pm

This last week marked another solid week for investors and many stocks were on the move.  We have compiled a list of stocks we are looking for event-driven trading moves ...
Read Full Story »

BioWatch: Oncothyreon Punishes Holders in Secondary Offering Discount (ONTY)

Posted: April 29, 2011 at 8:26 am

Oncothyreon Inc. (NASDAQ: ONTY) is doing what appears to be a small secondary stock offering to raise capital, but it is one of those offerings where the price comes at a ...
Read Full Story »

BioWatch: Amarin Joins Ten-Bagger Chase (AMRN)

Posted: April 18, 2011 at 9:17 am

Amarin Inc. (NASDAQ: AMRN) just went off the charts, literally.  The company reported very solid Phase III study results this morning and the stock is now up almost tenfold from ...
Read Full Story »

ETF Watch: Biotechs Fighting M&A Shrinkage (BBH, AMGN, GILD, BIIB, XBI, FBT, CRA, CEPH, IBB)

Posted: April 11, 2011 at 2:01 pm

Biotech is becoming the ever-shrinking stock sector.  It is almost weekly now that a new biotech acquisition is announced.  Big Pharma in the United States and large drugmakers internationally are all interested in ...
Read Full Story »